MedPath

Paediatric Ards Neuromuscular Blockade Study

Phase 4
Terminated
Conditions
ARDS
Interventions
Drug: Neuromuscular Blocking Agents
Drug: Isotonic saline
Registration Number
NCT02902055
Lead Sponsor
University Medical Center Groningen
Brief Summary

Paediatric acute respiratory distress syndrome (ARDS) is a manifestation of severe, life-threatening lung injury. Care for paediatric patient is mainly supportive and based on what works in adults and personal experiences, including the use of mechanical ventilation. However, differences in lung physiology and immunology between (young) children and adults suggests that adaptation of adult practices into paediatrics may not be justified. A study in adults with severe ARDS showed that early use of neuromuscular blocking agents (NMBA) improved 90-day survival and increased time off the ventilator without increasing muscle weakness. It is unknown if this is also true for paediatric ARDS

Detailed Description

Not available

Recruitment & Eligibility

Status
TERMINATED
Sex
All
Target Recruitment
3
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Rocuronium 1 mg/kg i.v.Neuromuscular Blocking AgentsNeuromuscular blocking agent
Isotonic salineIsotonic saline-
Primary Outcome Measures
NameTimeMethod
the cumulative respiratory morbidity score 12 months after PICU discharge, adjusted for confounding by age, gestational age, family history of asthma and/or allergy, season in which questionnaire was filled out and parental smoking12 months after PICU discharge
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

UMC Groningen

🇳🇱

Groningen, Netherlands

© Copyright 2025. All Rights Reserved by MedPath